Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2167 - Gender and chemotherapy-related toxicity in colon cancer: an analysis of the PETACC-3 trial conducted by the EORTC GI-group


08 Oct 2016


Poster Display


Valérie Cristina


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


V. Cristina1, J. Mahachie2, M. Mauer2, C. Csajka3, D. Cunningham4, E. van Cutsem5, A. Roth6, A.D. Wagner1

Author affiliations

  • 1 Département D'oncologie, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 2 Gi Group, EORTC, 1200 - Brussels/BE
  • 3 Division De Pharmacologie Clinique, Centre Hospitalier Universitaire Vaudois - CHUV, 1005 - Lausanne/CH
  • 4 Department Of Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 5 Gastro-enterology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 6 Group Cancer Gastro-intestinal, SAKK, 3008 - Bern/CH


Abstract 2167


Drug metabolism is genetically determined. Gender is one of the factors responsible for the large interpatient variability in the dose-effect relationship of cytotoxics. Comparative data on the effect of gender on chemotherapy (CT)-related toxicity are lacking in colon cancer.


This is a retrospective analysis of data from the PETACC-3 trial: 2974 pts (55.7% men (m) and 44.3% women (f)) with stage II and III colon cancer were treated with adjuvant 5-fluorouracil/leucovorin alone (5FU/LV) or with irinotecan (FOLFIRI). Primary aim was to compare CT-related toxicity (according to NCIC-CTCG) in m and f. Clinical and hematologic adverse events (AEs) rates and frequency of dose reductions in m and f were compared by Fisher's exact test; survival outcomes by log-rank test. Subgroup analyses were performed according to age (


Higher rates of all grade nausea (61.8 vs 53.7%, p 


In this trial, women demonstrated significantly greater rates of various hematological and non-hematological AEs, especially under treatment with FOLFIRI. Thus, AEs need to be reported according to gender in future clinical trials. Further data investigating the relationship between gender and CT efficacy and toxicity is required.

Clinical trial identification

Legal entity responsible for the study





D. Cunningham: Amgen, AstraZeneca, Bayer, Celgene, Medimmune, Merck Serono, Merrimack, Sanofi: Research funding to my institution. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings